Trials / Not Yet Recruiting
Not Yet RecruitingNCT07406334
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose
A Phase 1, Observer-Blind, Randomized, Active Controlled Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 To 15 Months of Age Receiving a Single Booster Dose
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 12 Months – 15 Months
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to assess the safety and reactogenicity of a single dose of the new pneumococcal vaccine (called Pn-MAPS30plus) in toddlers who have previously completed a two-dose primary vaccination series with PCV used in local immunization program. PCV20 will be used as a comparator for this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Pn-MAPS30plus | Pn-MAPS30plus vaccine will be administered intramuscularly. |
| COMBINATION_PRODUCT | PCV20 | PCV20 vaccine will be administered intramuscularly. |
Timeline
- Start date
- 2026-05-15
- Primary completion
- 2027-02-22
- Completion
- 2027-02-22
- First posted
- 2026-02-12
- Last updated
- 2026-02-12
Source: ClinicalTrials.gov record NCT07406334. Inclusion in this directory is not an endorsement.